Airway Medix S.A. zawiera trzecią międzynarodową umowę dystrybucyjną
W dniu 15 września 2025 r. Airway Medix podpisała trzyletnią umowę o wyłącznej dystrybucji Cuffix i Oral Care z dystrybutorem na Bliskim Wschodzie. Umowa przewiduje minimalne zamówienia o wartości około 0,3 mln EUR do 2027 r.
Pełna treść w języku angielskim (oryginał)
Warsaw, September 17, 2025: Airway Medix S.A. (WSE: AWM), an inspiring medical technology company, announced that on September 15, 2025, it secured its third consecutive international distribution agreement with a medical equipment distributor in a Middle Eastern country for exclusive sales of its Cuffix and Oral Care product lines.
The three-year exclusive distribution agreement will automatically extend for additional one-year periods and establishes a minimum order commitment of approximately EUR 0.3 million through 2027. Contract terms align with industry standards and mirror the Company's previously announced international partnerships.
This latest agreement marks another important step in the Company's global expansion and reflects the growing international appeal of Airway Medix's innovative medical solutions. Following two previously signed partnerships, the Company is now strengthening its international presence.
The Company is engaged in extensive discussions with distributors across numerous European and international markets. The feedback received to date has been highly positive, and the strong interest expressed by potential partners further reinforces the Company's confidence in the distinct value of its technologies.
"Securing three international partnerships in succession shows the strong market demand for our portfolio," said Anna Aranowska-Bablok, Chief Executive Officer of Airway Medix S.A. "Each new agreement brings us closer to our goal of making our innovative products available to healthcare providers worldwide, ultimately improving patient care where it's needed most. This momentum is further strengthened by our recent achievement of ISO 13485 certification and our advancing EU certification process for the expanded B-Care Oral Care medical device family under the Medical Devices Regulation, positioning us strongly for continued growth."
Airway Medix remains committed to expanding its network of trusted international partners while advancing the global availability of its solutions. The Company's pipeline of innovative technologies, supported by robust regulatory progress, underscores its long-term vision of delivering meaningful improvements in critical care worldwide.
About Airway Medix S.A.: Airway Medix S.A. focuses on the research, development and commercialization of innovative single-use devices for mechanically ventilated patients in Intensive Care Units (ICUs), as well as life-threatening patients and anesthesiology departments. The products offered by Airway Medix address the most pressing clinical needs and fill a gap in current medical devices. Airway Medix S.A. has been listed on the Warsaw Stock Exchange since 2014.
Komunikaty prasowe publikowane są w formie wydanej przez Airway Medix S.A. Informacje o produktach są zgodne z instrukcjami używania.
